Use of Epigenetic Modification to Induce FOXP3 Expression in Naïve T Cells

Moon, Chul Woo; Kim, S.H.; Park, K.S.; Choi, Bomi; Lee, Heesang; Park, J.B.; Choi, Gyu Seong; Kwan, Jae; Joh, Jae‐Won

doi:10.1016/j.transproceed.2009.02.101

Cited by 41 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, we used the histone deacetylase inhibitor TSA to promote acetylation of histones H3 and H4 to generate a hyper-acetylated chromatin state that promotes gene expression (29). Single treatment with either 5Ј-aza-dC (10 M) or TSA (100 nM) increases Bmp2 or Alp mRNA expression to a limited degree in 3T3-L1 cells (Fig.…”

Section: Epigenetic Modifications Enable Stimulation Of Bmp2 or Alp Ementioning

confidence: 99%

Epigenetic Modifications and Canonical Wingless/int-1 Class (WNT) Signaling Enable Trans-differentiation of Nonosteogenic Cells into Osteoblasts

Cho

Yoon

Kim

et al. 2014

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background:The cell type-specific induction of Bmp2 expression by Wnt3a indicates that Bmp2 is controlled by epigenetic mechanisms. Results: Epigenetic modification activates Bmp2 and Alp expression by Wnt3a in nonosteogenic cells. Conclusion: Epigenetic induction of Bmp2 production by Wnt3a reveals a new mechanistic dimension in morphogen-mediated control of osteogenesis. Significance: Epigenetic modifications/canonical Wnt3a signaling may provide a new method for trans-differentiation of nonosteogenic cells to osteoblasts.

show abstract

Section: Epigenetic Modifications Enable Stimulation Of Bmp2 or Alp Ementioning

confidence: 99%

Epigenetic Modifications and Canonical Wingless/int-1 Class (WNT) Signaling Enable Trans-differentiation of Nonosteogenic Cells into Osteoblasts

Cho

Yoon

Kim

et al. 2014

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…9,10 Preemptive AZA treatment for MRD has an acceptable safety profile and appears to be an effective strategy in pediatric patients with high-risk MDS after HSCT. There are little data available about AZA therapy after HSCT in pediatric MDS/AML, and therefore, further studies are needed.…”

Section: Discussionmentioning

confidence: 99%

Azacitidine in the Treatment of Pediatric Therapy-related Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Inoue

Kawakami

Takitani

et al. 2014

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

We herein present a case of pediatric therapy-related myelodysplastic syndrome (t-MDS) with complex karyotype who was treated with azacitidine (AZA) for AML1-EVI1 fusion transcript as minimal residual disease after allogeneic hematopoietic stem cell transplantation (HSCT). The patient was started on AZA 41 days after the HSCT without having achieved complete remission. After 9 cycles of AZA, the AML1-EVI1 fusion transcript disappeared, and there was no manifestation of graft versus host disease during AZA treatment. Preemptive AZA treatment for minimal residual disease has an acceptable safety profile and appears to be an effective strategy for preventing or substantially delaying hematological relapse in pediatric patients with high-risk myelodysplastic syndrome after HSCT.

show abstract

“…In addition, azacytidine may activate donorderived cytotoxic T lymphocytes and thereby may enhance the GVL effects after HSCT. [45][46][47][48] Although the exact implication of RICBT following low-dose azacytidine remains largely unknown, we had no patients with grade IV acute GVHD or extensive chronic GVHD. This is in accordance with a previous report that upregulation of regulatory T cells caused by low-dose azacytidine might induce cytotoxic T lymphocyte activity against tumor antigens.…”

Section: Discussionmentioning

confidence: 99%

A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies

Gotoh

Yoshizawa

Katagiri

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Non-remitting patients with hematologic myeloid malignancies have poor prognosis. To overcome this problem, we investigated the use of reduced-intensity preconditioning umbilical cord blood transplantation (RICBT) combined with recombinant G-CSF (rG-CSF) with high-dose Ara-C, fludarabine, melphalan, and 4 Gy of TBI in a phase I/II study in patients with non-remitting myeloid hematologic malignancies. Thirteen patients were enrolled, including 12 with non-remitting AML and one patient with blastic crisis CML (CML-BC). The patients' median age was 45 years, with a median comorbidity index of 4. All patients received 4/6 serological HLA-antigen matched unrelated umbilical cord blood. All patients were engrafted within 30 days after RICBT (median, 20 days; range, 14-29) and achieved complete remission without prior hematopoiesis. Common grade III non-hematologic toxicities included eight cases of transient mucositis (62%) and six cases of febrile neutropenia (46%). Transplant-related mortality was 7.7%. The 1-year overall survival was 28.6% in cases without post-RICBT treatment and 83.3% in cases with post-RICBT treatment. These data suggest that in active AML and CML-BC, the combination of rG-CSF with high-dose Ara-C and fludarabine/melphalan/4 Gy TBI with a reduced-intensity preconditioning regimen is well tolerated, secures engraftment and has significant anti-leukemia activity. In addition, performing post-RICBT treatment may provide high-quality long-term survival and remission.Bone Marrow Transplantation (2014) 49, 955-960;

show abstract

Use of Epigenetic Modification to Induce FOXP3 Expression in Naïve T Cells

Cited by 41 publications

References 28 publications

Epigenetic Modifications and Canonical Wingless/int-1 Class (WNT) Signaling Enable Trans-differentiation of Nonosteogenic Cells into Osteoblasts

Epigenetic Modifications and Canonical Wingless/int-1 Class (WNT) Signaling Enable Trans-differentiation of Nonosteogenic Cells into Osteoblasts

Azacitidine in the Treatment of Pediatric Therapy-related Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies

Contact Info

Product

Resources

About